MELBOURNE, AUSTRALIA / ACCESSWIRE / June 19, 2015 / Propanc Health Group Corporation (PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced a summary of Corporate and R&D activities currently underway as part of a shareholder update since presenting at the SeeThru Equity Conference last month.
Since the conference, research undertaken by Propanc’s research partners at the Universities of Jaen and Granada has produced some initial exciting results. Management and their research partners believe the data generated could result in patentable subject matter. Consequently, information will be released once further testing and evaluation is conducted and a final determination made on patentability of the subject matter.
Pilot animal studies are ongoing for PRP and results will be reported at the earliest opportunity when the data set is complete and reports are evaluated. Studies in several tumor types implanted in mice remain on track.
“We view these pilot studies as incremental, but important steps to understand the effects of PRP in numerous cancer cell types when administered by I.V injection,” said James Nathanielsz, Propanc’s Chief Executive Officer. “These studies are providing important information about the dosing and exposure of PRP, and hence, its potential safety profile prior to entering into animal toxicology studies, as well as human trials. We want to ensure that the data generated will assist with maximizing results when we enter the clinic.”
Additionally, the Company is seeking input from drug development experts and regulatory consultants as it considers the best time for meeting with healthcare regulatory agencies to obtain scientific advice for conducting the next stage of formal safety studies for PRP.
Propanc continues to field interest from potential investors willing to finance the Company’s R&D activities for PRP through the preclinical development stage in preparation for human trials. The management team is conscious this represents an opportunity to strengthen the Company’s financial position, but will consider terms carefully to ensure the long term future the Company and its shareholders.
In preparation for its proposed up-listing to a national exchange, the Company is working towards strengthening its Board of Advisors who could assist with execution of the Company’s strategic plan.
The Company also continues to carefully evaluate opportunities to fast track growth and strengthen the company’s portfolio. These opportunities will be carefully considered with the Company’s Advisors to determine their potential suitability. Nevertheless, management remains committed to identifying potential new projects, as part of its long term strategic objectives for growth.
We are a development stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our leading products are variations upon our novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we intend to submit our proenzyme treatment to the rigorous, formal non-clinical and clinical development and trial processes required to obtain the regulatory approval necessary to commercialize it and any product(s) derived and/or to be derived therefrom.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In the future, we intend to development our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, please visit: www.propanc.com.
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company’s ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company’s financial position. See Propanc’s most recent Quarterly Report on Form 10-Q and related 8K filings.